palomid 529

Palomid 529 is a small molecule inhibitor that targets the PI3K/AKT/mTOR signaling pathway by dissociating both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). It is a derivative of a non-steroidal estrogen antagonist but lacks estrogen receptor binding activity. Palomid 529 exhibits antiangiogenic and anticancer properties by inhibiting tumor growth, angiogenesis, and vascular permeability. The drug has been investigated primarily for oncology indications such as glioblastoma (where it has received orphan designation in the US) and prostate cancer, as well as ophthalmology indications like neovascular age-related macular degeneration (AMD), particularly in patients refractory to anti-VEGF therapy. It penetrates the blood-brain barrier in animal models[1][2][3][4][5][8].

Other names

RES-529RES529RES 529